Investment Rating - The report maintains a "Buy" rating for the company [4][7]. Core Insights - The company achieved a revenue of 5.539 billion yuan in 2024, representing a year-on-year growth of 57.2%, and a net profit attributable to shareholders of 2.062 billion yuan, up 42.1% year-on-year [1]. - The gross margin for 2024 was 82.1%, a decrease of 1.54 percentage points compared to the previous year, primarily due to increased sales costs and product type expansion [1]. - The company is a leader in collagen protein skincare products in China, focusing on R&D and expanding into eight consumer brands [4]. Revenue and Profit Forecast - The company is projected to achieve net profits attributable to shareholders of 2.575 billion yuan, 3.149 billion yuan, and 3.782 billion yuan for 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 25, 21, and 17 [4][6]. Brand Performance - The brand "可复美" generated revenue of 4.54 billion yuan in 2024, marking a 62.9% increase year-on-year, with strong performance in the dressing category [2]. - The "焦点" series, targeting skin sub-health populations, has shown promising sales, with the core product achieving a GMV of 277 million yuan within nine months of launch [2]. Channel Strategy - In 2024, the direct sales channel accounted for 74.6% of total sales, with online direct sales revenue reaching 3.587 billion yuan, a 66.5% increase year-on-year [3]. - The company has expanded its offline presence, covering approximately 1,700 public hospitals and 3,000 private hospitals and clinics, along with 6,000 retail stores [3].
巨子生物：2024年年报点评：大单品驱动收入利润高增，新品布局稳步推进-20250328